Genentech Biooncology
Genentech Biooncology
    • Home 

    • Tumor Types 

    • Colorectal Cancer 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
    • Breast Cancer
    • CLL
    • Colorectal Cancer
    • DLBCL
    • Follicular Lymphoma
    • Gastric Cancer
    • Glioblastoma
    • Lung Cancer
    • Melanoma
    • Multiple Myeloma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Renal Cell Carcinoma
    • Other Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Molecular Causes of Cancer
    • Evading immune destruction
  • Biological Pathways
    • Angiogenic Signaling
    • MET Signaling
  • Therapeutic Targets
    • MET
    • VEGF
  • Pipeline Molecules
    • Onartuzumab (MetMAb)
  • Research Education
    • ResearchBRAF
      • Oncogenic BRAF and prognosis
      • Oncogenic BRAF in cancer
    • ResearchMET
      • Companion Diagnostics and Biomarkers
      • Met Dysregulation in Cancer
      • Targeting Met
    • ResearchVEGF
      • Glossary
      • Role of Genentech BioOncology in VEGF research
      • Slide decks and videos
      • VEGF in colorectal cancer
      • Adjuvant fluoropyrimidines
      • VEGF as a predictive factor
      • Preoperative radiotherapy
      • VEGF and prognosis
      • Metastasis
      • Increased risk of relapse
      • Survival
      • Tumor invasion/lymph node involvement
      • Summary
      • Angiogenic switch activation
      • Evidence of VEGF expression
      • Angiogenesis and apoptosis
      • VEGF expression by stage
      • Importance of interstitial pressure
      • Triggers of VEGF production
  • Clinical Trials
    • Colorectal Cancer
  • Cancer Biomarkers
    • Colorectal Cancer
      • Oncogenic BRAF and prognosis
      • Oncogenic BRAF in cancer
      • VEGF in colorectal cancer
      • Adjuvant fluoropyrimidines
      • VEGF as a predictive factor
      • Preoperative radiotherapy
      • VEGF and prognosis
      • Metastasis
      • Increased risk of relapse
      • Survival
      • Tumor invasion/lymph node involvement
      • Summary
      • Evidence of VEGF expression
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • Emerging therapeutic options
      • Emerging therapeutic options
      • High VEGF expression
      • VEGF in bladder cancer
      • MVD and progression
      • Summary
      • VEGF and MVD
      • VEGF and prognosis
      • VEGF and progression
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • Regulation of VEGF expression
      • Serum VEGF as a clinical marker
      • Summary
      • VEGF expression in gastric cancer
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF and tumor progression in gastric cancer
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
    • Bispecific Monoclonal Antibodies
      • Emerging therapeutic options
      • Emerging therapeutic options
    • Glycoengineered Antibodies
      • HER Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Emerging therapeutic options
      • Emerging therapeutic options
      • High VEGF expression
      • VEGF in bladder cancer
      • MVD and progression
      • Summary
      • VEGF and MVD
      • VEGF and prognosis
      • VEGF and progression
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • Regulation of VEGF expression
      • Serum VEGF as a clinical marker
      • Summary
      • VEGF expression in gastric cancer
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF and tumor progression in gastric cancer
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
    • Non-Antibody Biologics
      • Apoptosis
      • High VEGF expression
      • VEGF in bladder cancer
      • MVD and progression
      • Summary
      • VEGF and MVD
      • VEGF and prognosis
      • VEGF and progression
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • Regulation of VEGF expression
      • Serum VEGF as a clinical marker
      • Summary
      • VEGF expression in gastric cancer
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF and tumor progression in gastric cancer
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
      • What are the strategies for inhibiting the VEGF pathway?
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Slide decks and videos
      • High VEGF expression
      • VEGF in bladder cancer
      • MVD and progression
      • Summary
      • VEGF and MVD
      • VEGF and prognosis
      • VEGF and progression
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • Regulation of VEGF expression
      • Serum VEGF as a clinical marker
      • Summary
      • VEGF expression in gastric cancer
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF and tumor progression in gastric cancer
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
      • What are the strategies for inhibiting the VEGF pathway?
      • Melanoma
      • Multiple Myeloma
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • B-cell Surface Proteins
      • HER Signaling
      • Parsatuzumab (Anti-EGFL7)
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • Emerging therapeutic options
      • Emerging therapeutic options
      • Glossary
      • Slide decks and videos
      • High VEGF expression
      • VEGF in bladder cancer
      • MVD and progression
      • Summary
      • VEGF and MVD
      • VEGF and prognosis
      • VEGF and progression
      • VEGF and progression in urothelial carcinoma
      • VEGF in gastric cancer
      • Regulation of VEGF expression
      • Serum VEGF as a clinical marker
      • Summary
      • VEGF expression in gastric cancer
      • VEGF, MVD, and metastases in gastric carcinoma
      • VEGF and tumor progression in gastric cancer
      • VEGF in multiple myeloma
      • Summary
      • VEGF expression in multiple myeloma
      • VEGF pathways in multiple myeloma
      • VEGF and prognosis in multiple myeloma
      • Hypoxic tumor environment promotes angiogenesis
      • VEGF in pancreatic cancer
      • Summary
      • VEGF expression and liver metastases
      • VEGF and prognosis in pancreatic cancer
      • VEGF and tumor progression in pancreatic cancer
      • What are the strategies for inhibiting the VEGF pathway?
      • Melanoma
Share Colorectal Cancer

Colorectal Cancer

Disease Information

Genentech BioOncology is dedicated to advancing the science of colorectal cancer therapy through comprehensive research programs and education. Colorectal cancer is cancer that begins in the colon or rectum.

Types of colorectal cancer

  • Adenocarcinomas constitute 95% of colorectal cancer and originate in mucus-producing glands lining the colon and rectum1
  • Carcinoid tumors develop from hormone-producing cells of the intestine1
  • Gastrointestinal stromal tumors develop from the interstitial cells of Cajal. They may be benign or malignant1
  • Lymphomas may start in the colon, rectum, or other organs1
  • Sarcomas can start in the blood vessels, muscle, and connective tissue of the colon and rectum wall1

Colorectal Cancer Demographics

  • In 2010, an estimated 102,900 Americans were diagnosed with colon cancer and 39,670 were diagnosed with rectal cancer2
  • An estimated 51,370 Americans died of colorectal cancer (9% of all cancer deaths)2
  • Colorectal cancer is the third most common cancer in both men and women2
  • Colorectal cancer incidence and mortality have declined over most of the past 2 decades, attributable to the increased use of colorectal cancer screening and consequent removal of precancerous polyps1,2

Colorectal Cancer Epidemiology

  • Risk factors include age >50 years; colorectal polyps; colorectal cancer in a first-degree relative; inherited syndromes like familial adenomatous polyposis or hereditary nonpolyposis colon cancer (Lynch syndrome); personal history of colorectal cancer or inflammatory bowel disease; diets high in fat and low in calcium, folate, and fiber; physical inactivity, obesity, cigarette smoking, and heavy alcohol use1
  • African Americans and Jews of Eastern European descent have a higher than normal incidence of colorectal cancer1,2
  • The 5-year relative survival rate for persons with colorectal cancer is 65%2

Symptoms of colorectal cancer include a change in bowel habits such as diarrhea, constipation, or narrowing of the stool; the sensation of incomplete bowel emptying; blood in the stool; cramps, flatulence, and bloating; unexplained weight loss; fatigue; nausea, and vomiting.1,3

Other links to colorectal cancer disease information

These links give a sampling of other sites offering information on colorectal cancer, which you may find useful in your practice.

  • National Cancer Institute at National Institutes of Health, Colon and Rectal Cancer
  • ASCO Cancer Portals - Gastrointestinal Cancers
  • Colorectal Cancer Facts & Figures 2011-2013

Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.

References:
1.
American Cancer Society. Colorectal cancer early detection. www.cancer.org/Cancer/ColonandRectumCancer/
DetailedGuide/colorectal-cancer-what-is-cancer
. Accessed April 13, 2011.
2.
American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-026238.pdf
. Accessed April 14, 2011.
3.
US Department of Health and Human Services. National Cancer Institute. What you need to know about™ cancer of the colon and rectum. www.cancer.gov/cancertopics/wyntk/colon-and-rectal/page1. Accessed April 13, 2011.
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: DLBCL »

© 2011 Genentech USA, Inc. All rights reserved